ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Cytyc Buys Pro-Duct Health, Ductal Lavage Device Maker. TAP To Pay $875 Million To Settle Federal Civil Suit.

October 26, 2001

Oral Complications Reduced By Pretherapy NIH Conference Finds

April 28, 1989

Implants Don’t Cause Cancer, Long-Term Study Finds

May 26, 2006

CCOP Review Completed; 72 Applications Submitted, 23 More For Minority CCOP

December 1, 1989

Human Embryo Panel Defines Acceptable Research For Funding

September 30, 1994

CCOP Budget Needs Hefty Increase To Fund 55 Awards At Requested Levels, Yates Says

January 30, 1987